References
1. Teteneva T.A., Kurkin A.V., Bogdanova E.L. Preventive medicine in russia: trends of development. Azimut nauchnykh issledovaniy: ekonomika i upravlenie [Azimuth of Scientific Researches: Economics and Management]. 2017; 6 (1): 185-7. (in Russian)
2. Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012-2013 years. The results of ECVD-RF. Kardiovaskulyar-naya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2014; 13 (6): 4-11. (in Russian)
3. Healthcare in Russia 2017: statistical collection. Moscow: Rosstat, 170 p. (in Russian)
4. Ametov A.S., Prudnikova M.A. Obesity and type 2 diabetes: modern aspects of pharmacotherapy. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2016; (4): 16-21. (in Russian)
5. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013; 17 (6): 851-9.
6. Mothe-Satney I., Filloux C., Amghar H., Pons C., et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012; 61 (9): 2311-9.
7. Kurokaw J., Nagano H., Ohara O., Kubota N., et al. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc Natl Acad Sci USA. 2011; 108 (29): 12072-7.
8. Yang H., Youm Y.H., Vandanmagsar B., Ravussin A., et al. Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J Immunol. 2010; 185 (3): 1836-45.
9. Feuerer M., Herrero L., Cipolletta D., Naaz A., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15 (8): 930-9.
10. Rocha V.Z., Folco E.J., Sukhova G., Shimizu K., et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res. 2008; 103: 467-76.
11. Bertola A., Ciucci T., Rousseau D., Bourlier V., et al. Diabetes. 2012; 61: 2238-47.
12. Schwarz V. Adipose tissue as an endocrine organ. Problemy En-docrinologii [Problems of Endocrinology]. 2009; 55 (1): 38-44. (in Russian)
13. Litvinova L.S., Kirienkova E.V., Mazunin I.O., Vasilenko M.A., Fat-takhov N.S. Insulin resistance pathogenesis in metabolic obesity. Biomed-itsinskaya khimiya [Problems of Medical Chemistry]. 2015; 61 (1): 70-82. (in Russian)
14. Ametov A.S., Prudnikova M.A. Chronic inflammation in development of a diabetes mellitus 2 types. In: Diabetes mellitus 2 types. Problems and decisions: Manual. 3rd ed., processed and added. Moscow: GEOTAR-Media; 2015. (in Russian)
15. Pitsavos C., Tampourlou M., Panagiotakos D.B., Skoumas Y., et al. Association between low-grade systemic inflammation and type 2 diabetes mellitus among men and women from the ATTICA Study. Rev Diabet Stud. 2007; 4 (2): 98-104.
16. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep. 2006; 6: 177-81.
17. Ametov A.S., Milovanova O.A., Prudnikovа M.A., Depyui T.I. Diabetic neuropathy in patients with type 2 diabetes: role of chronic inflammation. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2016; (2): 38-50. (in Russian)
18. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343-50.
19. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
20. Gummesson A., Nyman E., Knutsson M., Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19 (9): 1295-305.
21. Grams J., Garvey W.T. Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action. Curr Obes Rep. 2015; 4 (2): 287-302.
22. American Diabetes Association. Prevention or delay of type 2 diabetes: Standards of medical care in diabetes-2018. Diabetes Care. 2018; 41 (Suppl. 1): S51-4.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.
24. Goldstein D.J. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992; 16: 397-415.
25. Pastors J.G., Warshaw H., Daly A., Franz M., et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care. 2002; 25: 608-13.
26. Diagnosis, treatment, prevention of obesity and associated diseases (National clinical guidelines). St. Petersburg, 2017. (in Russian)
27. Lean M.E.J., et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018; 391: 541-51.
28. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999; 23: 1016-24.
29. Mkrtumyan A.M., et al. Indicators of vazoreguliruyushchy function of an endothelium at patients with a metabolic syndrome against the background of therapy by Reduksin. Effektivnaya farmakoterapiya v endokri-nologii [Effective pharmacotherapy in endocrinology]. 2008 (4): 18-24. (in Russian)
30. Dedov 1.1., Troshina E.A., Mazurina N.V., Galieva M.O., Logvinova O.V. The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity. Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; (1): 9-15. (in Russian)
31. Logvinova O.V., Galieva M.O., Mazurina N.V., Troshina E.A. The place of central-acting drugs in the algorithms of treatment of primary obesity. Ozhirenie i metabolizm [Obesity and Metabolism]. 2017; 14 (2): 18-23. (in Russian)
32. Ametov A.S. Report on the program spring. Effective treatment of obesity - a way of fight against Diabetes Mellipidus. Effektivnaya farma-koterapiya v endokrinologii [Effective pharmacotherapy in endocrinology]. 2013; Special Issue: 7-11. (in Russian)
33. Dedov 1.1., Mel’nichenko G.A., Romantsova T.I. The strategy of obesity management: the results of All-Russian observational program "Primavera". Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; 13 (1): 36-44. (in Russian)
34. Romantsova T.I., Poluboyarinova I.V., Roik O.V. Dynamics of adipose tissue changes measured by MRI in obese patients during Reduxin treatment. Ozhirenie i metabolizm [Obesity and Metabolism]. 2012; (4): 39-43. (in Russian)
35. Ametov A.S., et al. The role of lipotoxicity in achieving glycemic control in patients with type 2 diabetes and obesity. Meditsinskiy Sovet [Medical Council]. 2013; 6: 84-91. (in Russian)
36. Smirnova O.V. The role of metformin in the modern strategy of treatment and prevention of type 2 diabetes mellitus. Sakharni diabet [Diabetes Mellitus]. 2010; (3): 83-90. (in Russian)
37. Tokubuchi I., Tajiri Y., Iwata S., et al. Benefi cial eff ects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. PLoS One. 2017; 12 (2): e0171293.
38. Jing Y., Wu F., Li D., et al. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018; 461: 256-64.
39. Gagnon J., Sheppard E., Anini Y. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diabetes Obes Metab. 2013; 15 (3): 276-9.
40. DeFronzo R.A., et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia. 2016; 59: 1645-54.
41. Bahne E., et al. Involvement of Glucagon-like Peptide-1 in the Glucose-lowering effect of Metformin. Diabetes Obes Metab. 2016; 18 (10): 955-61.
42. Andrianova O.L., Kamaeva E.R., Amineva L.Kh., Mirsaeva G.Kh., Ibragimova L.A. Effective treatment of obesity in women of reproductive age. Vestnik novykh meditsinskikh tekhnologiy. Elektronnoe izdanie [Journal of New Medical Technologies. eJournal]. 2015; 9 (4): 35. (in Russian)
43. Batrak G.A. The efficacy of combined therapy by sibutramin and metformine in patients with abdominal obesity type. Vestnik Ivanovskoy meditsinskoy akademii [Bulletin of the Ivanovo Medical Academy]. 2015; 20 (3): 59-60. (in Russian)
44. Ryzhenkova E.M., Levchenko V.G., Gerus A.Yu., Bryzgalina S.M. Experience with the use Reduxine met when abdominal obesity in women with polycystic ovary syndrome. In: Topical issues of medicine in modern conditions Collection of scientific papers on the results of the international scientific-practical conference. 2016: 168-72. (in Russian)
45. Shuvalova I.G., Grebneva I.V. Optimization of diabetes mellitus type 2 treatment in a disease onset. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2015; (4): 76-81. (in Russian)
46. Guerrero-Romero F., Rodriguez-Moran M., Perez-Fuentes R. et al. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metab Syndr Relat Disord. 2008; 6 (1): 15-23.
47. Sari R., Esin Eray, Ozdem S., et al. Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. Clin Exp Med. 2010; 10: 179-84.